Showing results (231-240 of 245) with videos related to

Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Leukemia|June 15, 2026
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid LeukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Haematologica|November 6, 2025
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2025
Ziftomenib in Relapsed or Refractory NPM1-Mutated AMLEunice S Wang, Pau Montesinos, James Foran, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Nature Medicine|October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, Ross L Levine, Amy S Ruppert, et al.
Blood|July 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AMLUma M Borate, Ying Huang, Tara L Lin, et al.
Pageof 25